BioSpace News Archive

Selvita S.A., one of the largest contract research organizations in Europe, reported its preliminary financial results for Q2 and H1 2022*.

Laekna, a clinical-stage biotechnology company dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide, announced yesterday that the first patient recently received a dose in the LAE201INT2101 phase I/II study at Seoul National University Hospital.

Theravance Biopharma, Inc. will be participating in the following Fireside Chats, both of which will be webcast.

IDEAYA Biosciences, Inc. announced that it has initiated an Investigator Sponsored Trial, or IST, in coordination with St. Vincent’s Hospital, Sydney, to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma patients.

IVERIC bio, Inc. announced positive topline results from GATHER2, the Company’s second Phase 3 clinical trial of Zimura®, a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences.

MannKind Corporation announced that it has successfully completed a Phase 1 study of clofazimine inhalation suspension and is planning discussions with the U.S. Food and Drug Administration regarding results and the ongoing clinical program.

Merck, known as MSD outside the United States and Canada, announced that Robert M. Davis, chief executive officer and president, and Dr. Dean Li, president, Merck Research Laboratories, are scheduled to participate in a virtual fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, Sept. 12, 2022, at 2:15 p.m. EDT.

GlycoMimetics, Inc., a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, announced a poster presentation describing the rationale and design for the Phase 2 trial of LYT-100 in patients with IPF at the European Respiratory Society International Congress.